T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

Learn more about the potential long-term consequences and challenges a child may face if they have HDFN as an infant.

This study presents an optimized CRISPR-Cas12a system for large-scale genetic screening, revealing critical genes involved in ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Although DR5 has seemed an attractive target for cancer treatments, those developed so far haven't been ... cell types that have high levels of DR5 expression, including melanoma, liver and ...

In summary, enalapril significantly mitigated multiple pathological markers associated with aging, including lipid droplets, amyloid, glycogen deposition, and fibrosis, in the brain, kidneys, liver, ...